Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.

Saved in:
Bibliographic Details
Title: Long-term follow-up of MRD-guided ibrutinib plus venetoclax in relapsed CLL: phase 2 VISION/HO141 trial.
Authors: Niemann CU; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Dubois J; Department of Hematology, Cancer Center Amsterdam, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Nasserinejad K; Hovon Foundation, Erasmus MC University Medical Center, Rotterdam, The Netherlands., da Cunha-Bang C; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Kersting S; Department of Hematology, HagaZiekenhuis, Den Haag, The Netherlands., Enggaard L; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Veldhuis GJ; Department of Hematology, Antonius Ziekenhuis, Sneek, The Netherlands., Mous R; Department of Hematology, Universitair Medisch Centrum Utrecht, Utrecht, The Netherlands., Mellink CHM; Department of Human Genetics, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., van der Kevie-Kersemaekers AF; Department of Clinical Genetics, University Medical Center Utrecht, Utrecht, The Netherlands., Dobber JA; Laboratory of Special Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands., Poulsen CB; Department of Hematology, Zealand University Hospital, Roskilde, Denmark., Razawy W; Hovon Foundation, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Hollestein R; Hovon Foundation, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Frederiksen H; Department of Hematology, Odense University Hospital, Odense, Denmark., Janssens A; Department of Hematology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium., Schjødt I; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Dompeling EC; Department of Hematology, Isala Ziekenhuis, Zwolle, The Netherlands., Ranti J; Department of Hematology, Turku University Central Hospital, Turku, Finland., Brieghel C; Department of Hematology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark., Mattsson M; Department of Hematology, Uppsala University Hospital, Uppsala, Sweden., Bellido M; Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands., Tran HTT; Department of Hematology, Akershus University Hospital, Lørenskog, Norway., Kater AP; Hovon Foundation, Erasmus MC University Medical Center, Rotterdam, The Netherlands., Levin MD; Department of Internal Medicine, Albert Schweitzer Hospital, Dordrecht, The Netherlands.
Source: Blood advances [Blood Adv] 2025 Aug 12; Vol. 9 (15), pp. 3665-3675.
Publication Type: Journal Article; Clinical Trial, Phase II; Randomized Controlled Trial
Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2473-9537
DOI:10.1182/bloodadvances.2024015180